PBA
JANX icon

Paradigm Biocapital Advisors’s Janux Therapeutics JANX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,920,258
Closed -$71.4M – 39
2025
Q3 		$71.4M Hold
2,920,258
– – 2.03% 16
2025
Q2 		$67.5M Sell
2,920,258
-409,651
-12% -$10.8M 2.88% 10
2025
Q1 		$89.9M Sell
3,329,909
-186,077
-5% -$7.01M 4.12% 8
2024
Q4 		$188M Buy
3,515,986
+1,115,412
+46% +$59M 6.55% 5
2024
Q3 		$109M Buy
2,400,574
+836,122
+53% +$36.4M 3.69% 7
2024
Q2 		$65.5M Buy
+1,564,452
New +$73.5M 2.51% 15

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Paradigm Biocapital Advisors's JANX Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 2,920,258 shares — an estimated $71.4M sold.

Paradigm Biocapital Advisors first reported a position in JANX in Q2 2024 and held it in 6 quarters. The position peaked at $188M in Q4 2024. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Paradigm Biocapital Advisors reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,920,258 Janux Therapeutics shares in Q4 2025, an estimated $71.4M.
  • Paradigm Biocapital Advisors first reported a position in Janux Therapeutics in Q2 2024 and held it in 6 quarters.
  • Paradigm Biocapital Advisors's Janux Therapeutics position peaked at $188M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.